Patents by Inventor Ulrike Baschant

Ulrike Baschant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases
    Patent number: 11878048
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: January 23, 2024
    Assignee: Kymab Limited
    Inventors: Martina Rauner, Lorenz C. Hofbauer, Uwe Platzbecker, Ulrike Baschant
  • ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
    Publication number: 20210214456
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
    Type: Application
    Filed: June 11, 2019
    Publication date: July 15, 2021
    Inventors: Martina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI
  • USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS AND TREATMENT OF PRIMARY OR SECONDARY SCLEROSING DISEASES
    Publication number: 20200215154
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.
    Type: Application
    Filed: June 14, 2018
    Publication date: July 9, 2020
    Inventors: Martina RAUNER, Lorenz C. HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT
  • Method for the prophylactic or therapeutic treatment of glucocorticoid-induced osteoporosis
    Patent number: 8906858
    Abstract: The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or AP-1-mediated effects, for example by LIF treatment. The method may additionally comprise a method for the treatment of a medical condition associated with inflammation comprising inhibition of NF-KB activity, for example by glucocorticoid (GC) treatment. The present invention therefore also relates to a method for the treatment and/or prevention of glucocorticoid induced osteoporosis comprising the administration of an effective amount of LIF to a subject, preferably in combination with GC treatment.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 9, 2014
    Assignee: Fritz-Lipmann-Institut E. V. Leibniz-Institut fuer Altersforschung
    Inventors: Jan Tuckermann, Alexander Rauch, Susanne Ostermay, Ulrike Baschant